Therefore, the ARF-MDM2-p53 pathway may represent a therapeutic vulnerability for EBV-negative BL, while targeting the EBV latency products may be the Achilles’ heel for EBV-positive BL. This evidence concerns the gene CDKN2A and Burkitt lymphoma.